Factor XI is a substrate for oxidoreductases: Enhanced activation of reduced FXI and its role in antiphospholipid syndrome thrombosis

Journal of Autoimmunity

Volumn 39, Issue 3, 2012, Pages 121-129

  Giannakopoulos, Bill ^a   Gao, Lu ^a,b   Qi, Miao ^a   Wong, Jason W ^c   Yu, Demin M ^b   Vlachoyiannopoulos, Panayiotis G ^d   Moutsopoulos, Harry M ^d   Atsumi, Tatsuya ^e   Koike, Takao ^e   Hogg, Philip ^c   Qi, Jian C ^a   Krilis, Steven A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Allosteric disulfide bonds; Antiphospholipid syndrome; Factor XI; Oxidoreductases; Thioredoxin

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; OXIDOREDUCTASE; PROTEIN DISULFIDE ISOMERASE; THIOREDOXIN 1; THROMBIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISULFIDE BOND; ENZYME ACTIVATION; HUMAN; OXIDATION; PRIORITY JOURNAL; THROMBOSIS;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CASE-CONTROL STUDIES; CYSTEINE; DISULFIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XI; FACTOR XIA; FACTOR XIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROTEIN DISULFIDE-ISOMERASES; THIOREDOXINS; THROMBIN; THROMBOSIS;

EID: 84865394069     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.05.005     Document Type: Article

References (36)

1. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
2. Giannakopoulos B., Passam F., Ioannou Y., Krilis S.A. How we diagnose the antiphospholipid syndrome. Blood 2009, 113:985-994.
3. Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M., Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000, 342:696-701.
4. Yang D.T., Flanders M.M., Kim H., Rodgers G.M. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006, 126:411-415.
5. Passam F.H., Rahgozar S., Qi M., Raftery M.J., Wong J.W., Tanaka K., et al. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 2010, 116:1995-1997.
6. Ioannou Y., Zhang J.Y., Passam F.H., Rahgozar S., Qi J.C., Giannakopoulos B., et al. Naturally occurring free thiols within {beta}2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010, 116:1961-1970.
7. Passam F.H., Rahgozar S., Qi M., Raftery M.J., Wong J.W., Tanaka K., et al. Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost 2010, 8:1754-1762.
8. Ioannou Y., Zhang J.Y., Qi M., Gao L., Qi J.C., Yu D.M., et al. Novel assays of thrombogenic pathogenicity for the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen ss2-glycoprotein I. Arthritis Rheum 2011, 63:2774-2782.
9. Shi T., Iverson G.M., Qi J.C., Cockerill K.A., Linnik M.D., Konecny P., et al. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A 2004, 101:3939-3944.
10. Shi T., Giannakopoulos B., Iverson G.M., Cockerill K.A., Linnik M.D., Krilis S.A. Domain V of beta2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318. J Biol Chem 2005, 280:907-912.
11. Schmidt B., Ho L., Hogg P.J. Allosteric disulfide bonds. Biochemistry 2006, 45:7429-7433.
12. Schmidt B., Hogg P.J. Search for allosteric disulfide bonds in NMR structures. BMC Struct Biol 2007, 7:49.
13. Hogg P.J. Disulfide bonds as switches for protein function. Trends Biochem Sci 2003, 28:210-214.
14. Monod J., Wyman J., Changeux J.P. On the nature of allosteric transitions: a plausible model. J Mol Biol 1965, 12:88-118.
15. Matthias L.J., Yam P.T., Jiang X.M., Vandergraaff N., Li P., Poumbourios P., et al. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 2002, 3:727-732.
16. Azimi I., Wong J.W., Hogg P.J. Control of mature protein function by allosteric disulfide bonds. Antioxid Redox Signal 2010, 14:113-126.
17. Wong J.W.H., Hogg P.J. Allosteric disulfide bonds. Folding of disulfide proteins 2011, Springer. C.J. Rowen, S. Ventura (Eds.).
18. Ganderton T., Wong J.W.H., Schroeder C., Hogg P.J. Lateral self-association of von Willebrand Factor involves the Cys2431-Cys2453 disulfide/dithiol in the C2 domain. Blood 2011, 118:5312-5318.
19. Gailani D., Smith S.B. Structural and functional features of factor XI. J Thromb Haemost 2009, 7:75-78.
20. McMullen B.A., Fujikawa K., Davie E.W. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 1991, 30:2056-2060.
21. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
22. Foglieni C., Fulgenzi A., Ticozzi P., Pellegatta F., Sciorati C., Bellon D., et al. Protective effect of EDTA preadministration on renal ischemia. BMC Nephrol 2006, 7:5.
23. Emsley J., McEwan P.A., Gailani D. Structure and function of factor XI. Blood 2010, 115:2569-2577.
24. Fujikawa K., Chung D.W., Hendrickson L.E., Davie E.W. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986, 25:2417-2424.
25. Papagrigoriou E., McEwan P.A., Walsh P.N., Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006, 13:557-558.
26. Harris E.N., Chan J.K., Asherson R.A., Aber V.R., Gharavi A.E., Hughes G.R. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986, 146:2153-2156.
27. Wang X., Cheng Q., Xu L., Feuerstein G.Z., Hsu M.Y., Smith D.L., et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005, 3:695-702.
28. Wang X., Smith P.L., Hsu M.Y., Gailani D., Schumacher E.W., Ogletree M.L., et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006, 4:1982-1988.
29. Cho J., Furie B.C., Coughlin S.R., Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008, 118:1123-1131.
30. Jasuja R., Furie B., Furie B.C. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood 2010, 116:4665-4674.
31. Devreese K., Peerlinck K., Hoylaerts M.F. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 2010, 115:870-878.
32. Papagrigoriou E., McEwan P.A., Walsh P.N., Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006, 13:557-558.
33. Youinou P. Haralampos M. Moutsopoulos: a lifetime in autoimmunity. J Autoimmun 2010, 35:171-175.
34. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. J Autoimmun 2011, 37:59-62.
35. Rose N.R. The genetics of autoimmune thyroiditis: the first decade. J Autoimmun 2011, 37:88-94.
36. Mackay I.R., Leskovsek N.V., Rose N.R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010, 35:199-205.